Pfizer announces release of four generic drugs
PEAPACK, N.J. Pfizer’s generic pharmaceutical subsidiary announced Thursday that it had introduced four drugs to its product line.
Greenstone said it had introduced amoxicillin tablets in the 875 mg strength, a generic version of GlaxoSmithKline’s Amoxil; cefadroxil capsules in the 500 mg strength, a generic version of Warner Chilcott’s Duricef; cefdinir capsules in the 300 mg strength, a generic version of Abbott Labs’ Omnicef; and cefprozil tablets in the 250 mg and 500 mg strengths, a generic version of Bristol-Myers Squibb’s Cefzil.
The company said that the introduction of the products marked the beginning of a “new and more aggressive” business strategy, where it had previously marketed only authorized generics of off-patent Pfizer products.
FDA approves Galderma’s Epiduo Gel treatment for acne
ROCKVILLE, Md. The Food and Drug Administration has approved a new acne treatment by Galderma Laboratories, the agency announced Wednesday.
The treatment, Epiduo Gel, is known generically as adapalene and benzoyl peroxide and is used to treat acne vulgaris in patients aged 12 and older.
FDA records indicate the agency approved it Monday.
Galderma, based in Lausanne, Switzerland, had not made a statement about the approval at midday Wednesday.
Wyeth announces lay-offs at operations in Puerto Rico
SAN JUAN, Puerto Rico More than 200 Wyeth Pharmaceuticals employees in Puerto Rico will lose their jobs between the end of the year and February, according to the Associated Press.
The drug maker said it would lay off 276 workers as part of a restructuring plan and drop in demand. The company employs about 3,000 people in the territory.
A spokeswoman for the company said the availability of generics reduced demand for the anti-anxiety drug Effexor (venlafaxine hydrochloride) and the acid reflux disease drug Protonix (pantoprazole sodium).